Using mTOR inhibitors could weaken the promoting effect of IGF on the proliferation and viability of tumor cells, while combining IGF2 inhibitors could provide a better curative effect on patients with adrenocortical carcinoma [34]. The gene discussed is IGF2; the disease is adrenal cortex carcinoma.